18 mg retatrutide/tirzepatide blend overview covering overlapping incretin mechanisms, absent combination trials, major safety limits and COA verification.
This research blend combines 6 mg retatrutide with 12 mg tirzepatide. Both engage GIP and GLP-1 pathways, while retatrutide additionally engages the glucagon receptor.
No clinical trial establishes the exact combination. The overlap creates interaction and exposure questions that cannot be answered by adding the two ingredient literatures together.
Mechanism explains why a compound enters a research conversation. It does not establish that the compound is effective, appropriate or safe for a person.
Tirzepatide is a dual GIP/GLP-1 receptor agonist; retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. Combining them duplicates two receptor pathways and introduces an unvalidated mixture.
A theoretical increase in pathway coverage is not evidence of added benefit. It may also increase adverse effects or alter pharmacokinetics in ways that component trials did not test.
These are recurring questions in the published literature. They are research themes, not promised outcomes or personal recommendations.
In Phase 3 TRIUMPH-4 trial data, average weight loss reached 28.7% of body weight at 68 weeks on the 12 mg dose
Trial data suggest increased resting energy expenditure via glucagon receptor activation, distinct from GLP-1-only agonists
Phase 2a sub-study reported liver fat reduction of up to 86% at 12 mg, with 93% of participants reaching normal liver fat levels
Phase 3 T2D trial data show HbA1c reductions of up to 2.0%, with 82% of participants reaching HbA1c ≤6.5% in earlier Phase 2 data
Trial data reported relief from knee osteoarthritis pain and improved physical function scores in a Phase 3 sub-analysis
Trial data show favorable shifts in cardiovascular risk markers: reduced triglycerides, blood pressure, and non-HDL cholesterol
Phase 2 retatrutide trials and authorized-product tirzepatide data describe separate molecules in controlled settings. Neither dataset studies this mixture.
What the evidence cannot answer: The appropriate evidence statement is therefore component-level only. Any numeric match score or pathway rationale must not imply that the combination itself has been clinically validated.
Open the published batch report and match its COA number to the vial used in your research.
View Retatrutide 6 + Tirzepatide 12 COAResearch-market naming does not establish identity, concentration or purity. A useful certificate of analysis identifies the batch, analytical method and measured result. Match the COA number to the vial rather than relying on a site-wide percentage or a study of a different product.
Independent verification: every certificate of analysis carries a code you can check yourself at Peptide Test Canada, an independent third-party testing lab — you don't have to take our word for it.
Quantum publishes an individual report for this entry and keeps the broader lab-results archive available for comparison.
Overlapping incretin activity makes gastrointestinal effects, dehydration, glucose-lowering combinations, pancreatitis/gallbladder history and pregnancy context especially important.
Product status: Tirzepatide is an active ingredient in authorized medicines; retatrutide is investigational. Quantum’s combined RUO vial is not an authorized prescription product.
The tracker separates baseline screening, titration decisions, tolerance notes, monthly review and metabolic measurements.
Cadence, timing and cycle are owner-draft previews. Dose, dilution, titration, inventory, check-ins and change history remain inside the tracker after purchase.
Concise answers that keep mechanism, evidence, product quality and regulatory status separate.
This research blend combines 6 mg retatrutide with 12 mg tirzepatide. Both engage GIP and GLP-1 pathways, while retatrutide additionally engages the glucagon receptor.
Tirzepatide is a dual GIP/GLP-1 receptor agonist; retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. Combining them duplicates two receptor pathways and introduces an unvalidated mixture.
Phase 2 retatrutide trials and authorized-product tirzepatide data describe separate molecules in controlled settings. Neither dataset studies this mixture. There is no established combined pharmacokinetic, interaction, titration, efficacy or long-term safety model for this blend.
Tirzepatide is an active ingredient in authorized medicines; retatrutide is investigational. Quantum’s combined RUO vial is not an authorized prescription product.
This educational page does not provide a protocol. Published exposure, when available, is specific to the studied or authorized product and cannot be transferred to Quantum’s research-use-only material. Use the tracker only as an organizational record, not a substitute for qualified medical care.
Use the individual batch report to verify identity, analytical method, reported purity and COA number. Match that number to the vial; a general purity claim is not batch verification.